Press Resease

Myelofibrosis Treatment Market - Global Industry Analysis

Myelofibrosis Treatment Market by Diagnosis Type (Gene Mutation Analysis, Bone Marrow biopsy, Imaging Test, and Blood Tests), by Treatment Type (Chemotherapy, Blood Transfusions, Stem Cell Transplant, Splenectomy, Radiation Therapy, and Others), by Drug Type (Hydroxyurea, Immunomodulators, JAK Inhibitor, and Others), and by End-User (Hospitals, Clinics, and Bone Marrow Transplant Centers): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2024

Published Date: 11-Jul-2018 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3210 Status : Published

Global myelofibrosis treatment market expected to generate revenue of around USD 971.5 million by end of 2024, growing at CAGR of 6.73% between 2018 and 2024. Myelofibrosis is rare bone marrow cancer in which normal bone marrow tissues get changed with scarred tissue which reduces the production of blood cells and increases the production of mutated cells.

Description

The report covers forecast and analysis for the myelofibrosis treatment market on the global and regional level. The study provides historic data for 2016 and 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the myelofibrosis treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the myelofibrosis treatment market on a global level.

In order to give the users of this report a comprehensive view of the myelofibrosis treatment market, we have included competitive landscape and analysis of Porter’s Five Forces Model for the market. The study encompasses a market attractiveness analysis, where diagnosis type, treatment type, drug type, and end users segments are benchmarked based on their market size, growth rate, and general attractiveness. 

Global Myelofibrosis Treatment Market

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including merger and acquisitions, new drug launch, drug pipeline, agreements, partnerships, collaborations & joint ventures, R&D, and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trends analysis, the product portfolio of various companies according to the region.

The study provides a decisive view of the myelofibrosis treatment market by segmenting the market into diagnosis type, treatment type, drug type, end users, and regions. All the segments have been analyzed based on present and the future trends and the market is estimated from 2018 to 2024. Based on diagnosis type, the market is segmented into gene mutation analysis, bone marrow biopsy, an imaging test, and blood tests. Based on treatment type, the market is segmented into chemotherapy, blood transfusions, stem cell transplant, splenectomy, radiation therapy, and others. Based on drug type, the market is segmented into hydroxyurea, immunomodulators, JAK inhibitor, and others. Based on end users, the market is segmented into hospitals, clinics, and bone marrow transplant centers. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further categorization into major countries including the U.S., Canada, Germany, the UK, France, Spain, Italy, China, Japan, India, Brazil, and Mexico. This segmentation includes demand for myelofibrosis treatment based on individual diagnosis type, treatment type, drug type, and end users in all the regions and countries.

The report also includes detailed profiles of end players such as Eli Lilly and Company, Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Incyte Corporation, Merck & Co., Bristol-Myers Squibb Company, Novartis AG, Amgen Inc., and Celgene Corporation, among others.

The report segments the global myelofibrosis treatment market as follows:

Global Myelofibrosis Treatment Market: Diagnosis Type Segment Analysis

  • Gene Mutation Analysis
  • Bone Marrow Biopsy
  • Imaging Test
  • Blood Test

Global Myelofibrosis Treatment Market: Treatment Type Segment Analysis

  • Chemotherapy
  • Blood Transfusions
  • Stem Cell Transplant
  • Splenectomy
  • Radiation Therapy
  • Others

Global Myelofibrosis Treatment Market: Drug Type Segment Analysis

  • Hydroxyurea
  • Immunomodulators
  • JAK Inhibitors
  • Others

Global Myelofibrosis Treatment Market: End-User Segment Analysis

  • Hospitals
  • Clinics
  • Bone Marrow Transplant Centers

Global Myelofibrosis Treatment Market: Regional Segment Analysis 

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global MyelofibrosisTreatment Market, 2016 - 2022 (USD Million)
    • 2.2. Global MyelofibrosisTreatmentMarket: Snapshot
  •  
  • Chapter 3. Myelofibrosis treatment - Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Myelofibrosis treatment market drivers: Impact analysis
      • 3.2.2. Increase in the prevalence of Myelofibrosis
      • 3.2.3. High unmet clinical needs
      • 3.2.4. R&D for drug discovery and undergoing clinical trials
    • 3.3. Market Restraints
      • 3.3.1. Global Myelofibrosis treatment market restraints: Impact analysis
      • 3.3.2. High treatment cost
      • 3.3.3. Lack of awareness
    • 3.4. Opportunities
      • 3.4.1. Countries increase in awareness about disease
      • 3.4.2. New drug development
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by diagnosis type segment
      • 3.6.2. Market attractiveness analysis, by treatment type segment
      • 3.6.3. Market attractiveness analysis, by drug type segment
      • 3.6.4. Market attractiveness analysis, by end user segment
      • 3.6.5. Market attractiveness analysis, by regional segment
  •  
  • Chapter 4. Global Myelofibrosis treatment Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Myelofibrosis treatment Market: company market share, 2016
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. R&D
      • 4.2.5. Regional Expansion
    • 4.3. Price Trend Analysis
    • 4.4. Technology Portfolio
  •  
  • Chapter 5. Global Myelofibrosis treatment Market - Diagnosis Type Segment Analysis
    • 5.1. Global Myelofibrosis treatment Market: Diagnosis Type overview
      • 5.1.1. Global Myelofibrosis treatment market revenue share, by Diagnosis Type, 2016 and 2022
    • 5.2. Gene Mutation Analysis
      • 5.2.1. Global Gene Mutation Analysis Market, 2016 - 2022(USD Million)
    • 5.3. Bone Marrow Biopsy
      • 5.3.1. Global Bone Marrow Biopsy Market, 2016 - 2022(USD Million)
    • 5.4. Imaging Test
      • 5.4.1. Global Imaging Test Market, 2016 - 2022(USD Million)
    • 5.5. Blood Test
      • 5.5.1. Global Blood Test Market, 2016 - 2022(USD Million)
  •  
  • Chapter 6. Global Myelofibrosis treatment Market - Treatment Type Segment Analysis
    • 6.1. Global Myelofibrosis treatment: Treatment Type overview
      • 6.1.1. Global Myelofibrosis treatment Marketrevenue share, by Treatment Type, 2016 and 2022
    • 6.2. Chemotherapy
      • 6.2.1. Global chemotherapy Market, 2016 - 2022 (USD Million)
    • 6.3. Blood Transfusion
      • 6.3.1. Global Blood Transfusion Market,2016 - 2022(USD Million)
    • 6.4. Stem Cell Transplant
      • 6.4.1. Global Stem cell transplant Market, 2016 - 2022(USD Million)
    • 6.5. Splenectomy
      • 6.5.1. Global Splenectomy Market , 2016 - 2022(USD Million)
    • 6.6. Radiation Therapy
      • 6.6.1. Global Radiation Therapy Market, 2016 - 2022(USD Million)
    • 6.7. Others
      • 6.7.1. Global Others Market, 2016 - 2022(USD Million)
  •  
  • Chapter 7. Global Myelofibrosis Treatment Market - Drug Type Segment Analysis
    • 7.1. Global Myelofibrosis treatment market: drug type overview
      • 7.1.1. Global Myelofibrosis treatment market revenue share, by drug type, 2016 and 2022
    • 7.2. Hydroxyurea
      • 7.2.1. Global Hydroxyurea Market, 2016 - 2022(USD Million)
    • 7.3. Immunomodulators
      • 7.3.1. Global Immunomodulators Market, 2016 - 2022(USD Million)
    • 7.4. JAK Inhibitors
      • 7.4.1. Global JAK Inhibitors Market, 2016 -2022(USD Million)
    • 7.5. Others
      • 7.5.1. Global Others Market, 2016 - 2022(USD Million)
  •  
  • Chapter 8. Global Myelofibrosis Treatment Market - End User Segment Analysis
    • 8.1. Global Myelofibrosis treatment Market: End User segment overview
      • 8.1.1. Global Myelofibrosis treatment Market revenue share, by end user, 2016 and 2022
    • 8.2. Hospitals
      • 8.2.1. Global Hospitals Market, 2016 - 2022(USD Million)
    • 8.3. Clinics
      • 8.3.1. Global Clinics Market, 2016 - 2022(USD Million)
    • 8.4. Bone Marrow Transplant Centers
      • 8.4.1. Global Bone marrow transplant centers Market, 2016 -2022(USD Million)
  •  
  • Chapter 9. Global Myelofibrosis treatment Market - Regional Segment Analysis
    • 9.1. Global Myelofibrosis treatment Market: Regional overview
      • 9.1.1. Global Myelofibrosis treatment Market revenue share, by region, 2016 and 2022
    • 9.2. North America
      • 9.2.1. North America Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022 (USD Million)
      • 9.2.2. North America Myelofibrosis treatment market revenue, by diagnosis type, 2014 - 2022 (USD Million)
      • 9.2.3. North America Myelofibrosis treatment market revenue, by treatment type, 2014 - 2022 (USD Million)
      • 9.2.4. U.S.
        • 9.2.4.1. U.S. Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.2.4.2. U.S. Myelofibrosis treatment market revenue, by Treatment type, 2014 - 2022 (USD Million)
        • 9.2.4.3. U.S. Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.2.4.4. U.S. Myelofibrosis treatment market revenue, by End User, 2014 - 2022 (USD Million)
      • 9.2.5. Canada
        • 9.2.5.1. Canada Myelofibrosis treatment revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.2.5.2. Canada Myelofibrosistreatment market revenue, by Treatment type, 2014 - 2022 (USD Million)
        • 9.2.5.3. Canada Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.2.5.4. Canada Myelofibrosis treatment market revenue, End User, 2014 - 2022 (USD Million)
      • 9.2.6. Rest of North America
        • 9.2.6.1. Rest of North America Myelofibrosis treatmentmarket revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.2.6.2. Rest of North America Myelofibrosis treatment market revenue, by Treatment type, 2014 - 2022(USD Million)
        • 9.2.6.3. Rest of North America Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.2.6.4. Rest of North America Myelofibrosis treatment market revenue, by End User, 2014 - 2022 (USD Million)
    • 9.3. Europe
      • 9.3.1. Europe Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
      • 9.3.2. Europe Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
      • 9.3.3. Europe Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
      • 9.3.4. Europe Myelofibrosis treatment market revenue, by End User, 2014 - 2022 (USD Million)
      • 9.3.5. Germany
        • 9.3.5.1. Germany Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.3.5.2. Germany Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.3.5.3. Germany Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.3.5.4. Germany Myelofibrosis treatment market revenue, by End User, 2014 - 2022 (USD Million)
      • 9.3.6. France
        • 9.3.6.1. France Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.3.6.2. France Myelofibrosis treatment market revenue, by Treatmnet type , 2014 - 2022(USD Million)
        • 9.3.6.3. France Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.3.6.4. France Myelofibrosis treatment market revenue, by End User, 2014 - 2022 (USD Million)
      • 9.3.7. UK
        • 9.3.7.1. UK Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.3.7.2. UK Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.3.7.3. UK Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.3.7.4. UK Myelofibrosis treatment market revenue, by End User, 2014 - 2022 (USD Million)
      • 9.3.8. Italy
        • 9.3.8.1. Italy Myelofibrosis treatment revenue market, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.3.8.2. Italy Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.3.8.3. Italy Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.3.8.4. Italy Myelofibrosis treatment market revenue, by End User, 2014 - 2022 (USD Million)
      • 9.3.9. Spain
        • 9.3.9.1. Spain Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.3.9.2. Spain Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.3.9.3. Spain Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.3.9.4. Spain Myelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
      • 9.3.10. Russia
        • 9.3.10.1. Russia Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.3.10.2. RussiaMyelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.3.10.3. Russia Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.3.10.4. RussiaMyelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
      • 9.3.11. Rest of Europe
        • 9.3.11.1. Rest of Europe Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.3.11.2. Rest of EuropeMyelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.3.11.3. Rest of Europe Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.3.11.4. Rest of EuropeMyelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022, (USD Million)
      • 9.4.2. Asia Pacific Myelofibrosis treatment market revenue, by treatment type , 2014 - 2022(USD Million)
      • 9.4.3. Asia PacificMyelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
      • 9.4.4. Asia PacificMyelofibrosis treatment market revenue, by End User, 2014 - 2022 (USD Million)
      • 9.4.5. China
        • 9.4.5.1. China Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.4.5.2. ChinaMyelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.4.5.3. China Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.4.5.4. ChinaMyelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
      • 9.4.6. Japan
        • 9.4.6.1. Japan Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.4.6.2. JapanMyelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.4.6.3. Japan Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.4.6.4. JapanMyelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
      • 9.4.7. India
        • 9.4.7.1. India Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.4.7.2. IndiaMyelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.4.7.3. India Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.4.7.4. IndiaMyelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
      • 9.4.8. Australia
        • 9.4.8.1. Australia Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.4.8.2. AustraliaMyelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.4.8.3. Australia Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.4.8.4. AustraliaMyelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
      • 9.4.9. Rest of Asia Pacific
        • 9.4.9.1. Rest of Asia Pacific Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.4.9.2. Rest of Asia PacificMyelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.4.9.3. Rest of Asia Pacific Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.4.9.4. Rest of Asia PacificMyelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
    • 9.5. Latin America
      • 9.5.1. Latin America Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022, (USD Million)
      • 9.5.2. Latin America Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
      • 9.5.3. Latin America Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
      • 9.5.4. Latin America Myelofibrosis treatment market revenue, by End User, 2014 - 2022 (USD Million)
      • 9.5.5. Mexico
        • 9.5.5.1. Mexico Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.5.5.2. MexicoMyelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.5.5.3. Mexico Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.5.5.4. MexicoMyelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
      • 9.5.6. Brazil
        • 9.5.6.1. Brazil Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.5.6.2. BrazilMyelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.5.6.3. Brazil Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.5.6.4. BrazilMyelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
      • 9.5.7. Argentina
        • 9.5.7.1. Argentina Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.5.7.2. Argentina Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.5.7.3. Argentina Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.5.7.4. ArgentinaMyelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
      • 9.5.8. Rest of Latin America
        • 9.5.8.1. Rest of Latin America Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.5.8.2. Rest of Latin America Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.5.8.3. Rest of Latin America Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.5.8.4. Rest of Latin AmericaMyelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
    • 9.6. Middle East and Africa
      • 9.6.1. Middle East and Africa Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022, (USD Million)
      • 9.6.2. Middle East and Africa Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
      • 9.6.3. Middle East and Africa Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
      • 9.6.4. Middle East and Africa Myelofibrosis treatment market revenue, by End User, 2014 - 2022 (USD Million)
      • 9.6.5. Saudi Arabia
        • 9.6.5.1. Saudi Arabia Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.6.5.2. Saudi Arabia Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.6.5.3. Saudi Arabia Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.6.5.4. Saudi ArabiaMyelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
      • 9.6.6. UAE
        • 9.6.6.1. UAE Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.6.6.2. UAE Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.6.6.3. UAE Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.6.6.4. UAE Myelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
      • 9.6.7. South Africa
        • 9.6.7.1. South Africa Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.6.7.2. South Africa Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.6.7.3. South Africa Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.6.7.4. South Africa Myelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
      • 9.6.8. Qatar
        • 9.6.8.1. Qatar Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.6.8.2. Qatar Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.6.8.3. Qatar Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.6.8.4. Qatar Myelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
      • 9.6.9. Rest of Middle East & Africa
        • 9.6.9.1. Rest of Middle East &Africa Myelofibrosis treatment market revenue, by Diagnosis type, 2014 - 2022(USD Million)
        • 9.6.9.2. Rest of Middle East & Africa Myelofibrosis treatment market revenue, by Treatment type , 2014 - 2022(USD Million)
        • 9.6.9.3. Rest of Middle East & Africa Myelofibrosis treatment market revenue, by Drug type, 2014 - 2022 (USD Million)
        • 9.6.9.4. Rest of Middle East & Africa Myelofibrosis treatment market revenue, by End User , 2014 - 2022(USD Million)
  •  
  • Chapter 10. Company Profile
    • 10.1. Eli Lilly and Company
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Diagnosis type portfolio
      • 10.1.4. Business strategy
      • 10.1.5. Recent developments
    • 10.2. Novartis AG
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Diagnosis type portfolio
      • 10.2.4. Business strategy
      • 10.2.5. Recent developments
    • 10.3. Gilead Sciences Inc.
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Diagnosis type portfolio
      • 10.3.4. Business strategy
      • 10.3.5. Recent developments
    • 10.4. F. Hoffmann-La Roche Ltd.
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Diagnosis type portfolio
      • 10.4.4. Business strategy
      • 10.4.5. Recent developments
    • 10.5. Incyte Corporation
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Diagnosis type portfolio
      • 10.5.4. Business strategy
      • 10.5.5. Recent developments
    • 10.6. Merck & Co.
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Diagnosis type portfolio
      • 10.6.4. Business strategy
      • 10.6.5. Recent developments
    • 10.7. Bristol-Myers Squibb Company
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Diagnosis type portfolio
      • 10.7.4. Business strategy
      • 10.7.5. Recent developments
    • 10.8. Amgen Inc.
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Diagnosis type portfolio
      • 10.8.4. Business strategy
      • 10.8.5. Recent developments
    • 10.9. Celgene Corporation
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Diagnosis type portfolio
      • 10.9.4. Business strategy
      • 10.9.5. Recent developments

List of Figures 

1. Market research process
2. Market research methodology
3. Global Myelofibrosis treatment market revenue, 2016 - 2022(USD Million) 
4. Porter’s five forces analysis
5. Myelofibrosis treatment market attractiveness analysis, by Diagnosis type segment
6. Myelofibrosis treatment Market: Market attractiveness analysis, by Treatment Type segment
7. Myelofibrosis treatment market: Market attractiveness analysis, by Drug type segment
8. Myelofibrosis treatment market: Market attractiveness analysis, by End User segment
9. Myelofibrosis treatment Market: Market attractiveness analysis, by Regional segment
10. Company market share analysis, 2016
11. Global Myelofibrosis treatment market revenue share by Diagnosis type, 2016 and 2022
12. Global gene mutation analysis market, 2014 – 2022 (USD Million)
13.  Global bone marrow biopsy market, 2014 – 2022(USD Million)
14. Global imaging test market, 2014 – 2022(USD Million)
15. Global blood test  market, 2014 – 2022(USD Million)
16. Global Competitive Myelofibrosis treatment, 2014 – 2022 (USD Million)
17. Global Myelofibrosis treatment market revenue share by Treatment types, 2014 and 2022
18.  Global chemotherapy market, 2014 – 2022, (USD Million) 
19.  Global blood transfusions market, 2014 – 2022, (USD Million) 
20. Global stem cell transplant market, 2014 – 2022, (USD Million)
21. Globalsplenectomy market, 2014 – 2022, (USD Million)
22. Global radiation therapy market, 2014 – 2022, (USD Million)
23. Global others market, 2014 – 2022, (USD Million)
24.  Global Myelofibrosis treatment market revenue share by Drug type, 2016 and 2022
25. Global hydroxyurea market, 2014 - 2022, (USD Million)
26. Global immunomodulators market , 2014 – 2022, (USD Million)
27. Global JAK inhibitors market, 2014 – 2022, (USD Million)
28. Global others market, 2014 – 2022, (USD Million)


List of Tables

1. Myelofibrosis treatment: Market Snapshot                                                                                                                        
2. Drivers of global Myelofibrosis treatment market: Impact analysis 
3. Restraints of global Myelofibrosis treatment market: Impact analysis  
4. North America Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
5. North America Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
6. North America Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
7. North America Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million)
8. U.S. Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
9. U.S. Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
10. U.S. Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
11. U.S. Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million)
12. Canada Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
13. Canada Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
14. Canada Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
15. Canada Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million)
16.  Rest of North America Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
17. Rest of North America Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
18. Rest of North America Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
19. Rest of North America Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million)
20. Europe myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022(USD Million)
21.  Europe Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
22. Europe Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
23. Europe Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
24.  U.K. myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022(USD Million)
25.  U.K.  Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
26. U.K.  Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
27. U.K.  Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
28.  Germany myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022(USD Million)
29.  Germany Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
30. Germany Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
31. Germany Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
32.  France myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022(USD Million)
33.  France Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
34. France Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
35. France Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
36.  Italy Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
37. Italy Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
38. ItalyMyelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
39. ItalyMyelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million)
40.  Spain Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
41. Spain Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
42. SpainMyelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
43. SpainMyelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
44.  Russia Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
45. Russia Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
46. RussiaMyelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
47. RussiaMyelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
48.  Rest of Europe Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
49. Rest of Europe Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
50. Rest of EuropeMyelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
51. Rest of EuropeMyelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
52. Asia Pacific Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
53. Asia Pacific Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
54. Asia Pacific Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
55. Asia Pacific Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
56. China Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
57. China Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
58. China Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
59. China Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
60. Japan Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
61. Japan Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
62. Japan Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
63. Japan Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
64. India Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
65. India Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
66. India Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
67. India Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
68.  Australia Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
69. Australia Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
70. Australia Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
71. Australia Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
72.  Rest of Asia Pacific Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
73. Rest of Asia Pacific Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
74. Rest of Asia Pacific Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
75. Rest of Asia Pacific Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
76.  Latin America Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
77. Latin America Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
78. Latin America Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
79. Latin America Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
80.  Mexico Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
81. MexicoMyelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
82. MexicoMyelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
83. MexicoMyelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
84.  Brazil Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
85. Brazil Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
86. Brazil Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
87. Brazil Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
88.  Argentina Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
89. Argentina Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
90. Argentina Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
91. Argentina Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
92.  Rest of Latin America Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
93. Rest of Latin America Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
94. Rest of Latin America Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
95. Rest of Latin America Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
96.  The Middle East and Africa Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
97. Middle East and Africa Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
98. Middle East and Africa Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
99. Middle East and Africa Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
100. Saudi Arabia Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
101. Saudi Arabia Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
102. Saudi Arabia Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
103. Saudi Arabia Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
104.  UAE Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
105. UAE Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
106. UAE Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
107. UAE Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
108.  South Africa Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
109. South Africa Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
110. South Africa Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
111. South Africa Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
112.  Qatar Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
113. Qatar Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
114. Qatar Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
115. Qatar Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 
116.  Rest of the Middle East & Africa Myelofibrosis treatment market revenue, by Diagnosis type, 2014 – 2022 (USD Million) 
117. Rest of Middle East & Africa Myelofibrosis treatment revenue, by Treatment type, 2014 – 2022 (USD Million) 
118. Rest of Middle East & Africa Myelofibrosis treatment market revenue, by Drug type, 2014 – 2022, (USD Million) 
119. Rest of the Middle East & Africa Myelofibrosis treatment market revenue, by End User type, 2014 – 2022, (USD Million) 

Methodology

Free Analysis

Myelofibrosis is a bone marrow cancer or a serious type of leukemia which affects the normal production of blood cells resulting in weakness, anemia, fatigue, and often enlarged spleen. This disease is caused due to the genetic mutation in blood stem cells. These mutated cells keep on dividing themselves which leads to the reduction of red blood cells and can lead to anemia. These genetic mutations in the cells can be caused by various factors such as exposure to radiation, certain chemicals such as benzene or toluene, and other blood cell-related disorders. This disease can be diagnosed by physical examination, blood tests, imaging tests, and bone marrow examination to confirm the presence of disease. Various symptoms such as feeling tired and weak, shortness of breath, fever, easy bleeding, a feeling of pain in bones and joint are observed in the patients of myelofibrosis. This condition can be treated by different therapies, medication, or stem cell transplant.

The epidemiology of myelofibrosis is increasing in the developing economies which results in the increase in demand for treatment options over the forecast period. There are various companies conducting research studies and investing a lot of money in R&D for the development of myelofibrosis drug. There are various drugs which are currently developed by different companies such as CYT387 which is being developed by Gilead Sciences Inc.; CTI BioPharma is trying to modify Pactritinib so that it can be used for the treatment of myelofibrosis and others. Increase in genetic disorders, smoking, reimbursement conditions, and living conditions are also expected to support the growth of myelofibrosis treatment market over the forecast period.

Global Myelofibrosis Treatment Market

Based on the diagnosis type, the myelofibrosis treatment market is segmented into gene mutation, bone marrow biopsy, an imaging test, and blood tests. Treatment type segmentation includes chemotherapy, blood transfusions, stem cell transplant splenectomy, radiation therapy, and others. Based on drug type, the myelofibrosis market is segmented into hydroxyurea, immunomodulators, JAK inhibitors, and others. On the basis of the end user, the myelofibrosis treatment market is segmented into hospitals, clinics, and bone marrow transplant centers.

North America is expected to remain the dominant region over the forecast period which is closely followed by Europe. Due to an increase in the prevalence of myelofibrosis in these regions and an increase in R&D for drug development are aspects expected to support the growth of the myelofibrosis treatment market. The Asia Pacific is expected to be the third largest growing region for the myelofibrosis treatment market due to increase in healthcare facilities, increase in disposable income and an increase in the prevalence of disease. Latin America and the Middle East and Africa are expected to grow moderately over the forecast period.

Some of the key players in myelofibrosis treatment market include Eli Lilly and Company, Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Incyte Corporation, Merck & Co., Bristol-Myers Squibb Company, Novartis AG, Amgen Inc., and Celgene Corporation, among others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed